資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31598
|
| 標題: | Recombinant adeno-associated virus vector carrying the thrombomodulin lectin-like domain for the treatment of abdominal aortic aneurysm |
| 作者: | Lai, Chao-Han
Wang, Kuan-Chieh
Kuo, Cheng-Hsiang
Lee, Fang-Tzu
Cheng, Tsung-Lin
Chang, Bi-Ing
Yang, Yu-Jen
Shi, Guey-Yueh
Wu, Hua-Lin |
| 貢獻者: | Natl Cheng Kung Univ,Natl Cheng Kung Univ Hosp, Dept Surg, Coll Med
Natl Cheng Kung Univ, Coll Med, Cardiovasc Res Ctr
Natl Cheng Kung Univ, Dept Biochem & Mol Biol, Coll Med
Chia Nan Univ Pharm & Sci, Dept Tourism Management, Coll Recreat & Hlth Management
Kaohsiung Med Univ, Dept Physiol, Coll Med
Kaohsiung Med Univ, Coll Med, Orthopaed Res Ctr |
| 關鍵字: | Adeno-associated virus
Thrombomodulin
Abdominal aortic aneurysm
Receptor for advanced glycation end
product
High-mobility group box 1
Inflammation |
| 日期: | 2017-07 |
| 上傳時間: | 2018-11-30 15:49:41 (UTC+8) |
| 出版者: | Elsevier Ireland Ltd |
| 摘要: | Background and aims: Thrombomodulin (TM), through its lectin-like domain (TMD1), sequesters proinflammatory high-mobility group box 1 (HMGB1) to prevent it from engaging the receptor for advanced glycation end product (RAGE) that sustains inflammation and tissue damage. Our previous study demonstrated that short-term treatment with recombinant TM containing all the extracellular domains (i.e., rTMD123) inhibits HMGB1-RAGE signaling and confers protection against CaCl2-induced AAA formation. In this study, we attempted to further optimize TM domains, as a potential therapeutic agent for AAA, using the recombinant adeno-associated virus (AAV) vector. Methods: The therapeutic effects of recombinant TMD1 (rTMD1) and recombinant AAV vectors carrying the lectin-like domain of TM (rAAV-TMD1) were evaluated in the CaCl2-induced AAA model and angiotensin II-infused AAA model, respectively. Results: In the CaCl2-induced model, treatment with rTMD1 suppressed the tissue levels of HMGB1 and RAGE, macrophage accumulation, elastin destruction and AAA formation, and the effects were comparable to a mole-equivalent dosage of rTMD123. In the angiotensin II-infused model, a single intravenous injection of rAAV-TMD1 (1011 genome copies), which resulted in a persistently high serum level of TMD1 for at least 12 weeks, effectively attenuated AAA formation with suppression of HMGB1 and RAGE levels and inhibition of proinflammatory cytokine production, macrophage accumulation, matrix metalloproteinase activities and oxidative stress in the aortic wall. Conclusions: These findings corroborate the therapeutic potential of the TM lectin-like domain in AAA. The attenuation of angiotensin II-infused AAA by one-time delivery of rAAV-TMD1 provides a proof-ofconcept validation of its application as potential gene therapy for aneurysm development. (C) 2017 Elsevier B.V. All rights reserved. |
| 關聯: | Atherosclerosis, v.262, pp.62-70 |
| 顯示於類別: | [觀光事業管理系(含溫泉所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1611 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
